Pacira BioSciences (PCRX) | Financial Analysis & Statements
Pacira BioSciences Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
196.9M
Gross Profit
156.6M
79.53%
Operating Income
3.2M
1.62%
Net Income
1.6M
0.83%
EPS (Diluted)
$0.04
Balance Sheet Metrics
Total Assets
1.3B
Total Liabilities
571.8M
Shareholders Equity
693.1M
Debt to Equity
0.82
Cash Flow Metrics
Operating Cash Flow
22.1M
Free Cash Flow
43.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Pacira BioSciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 726.4M | 701.0M | 675.0M | 666.8M | 541.5M |
| Cost of Goods Sold | 149.7M | 170.4M | 184.7M | 199.3M | 140.3M |
| Gross Profit | 576.7M | 530.5M | 490.3M | 467.5M | 401.3M |
| Gross Margin % | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% |
| Operating Expenses | |||||
| Research & Development | 117.3M | 81.6M | 76.3M | 84.8M | 55.5M |
| Selling, General & Administrative | 368.8M | 294.1M | 269.4M | 254.5M | 199.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 486.1M | 375.7M | 345.7M | 339.3M | 254.9M |
| Operating Income | 33.3M | 97.6M | 87.3M | 70.9M | 132.8M |
| Operating Margin % | 4.6% | 13.9% | 12.9% | 10.6% | 24.5% |
| Non-Operating Items | |||||
| Interest Income | 22.7M | 19.7M | 11.4M | 4.5M | 896.0K |
| Interest Expense | 14.6M | 13.4M | 17.3M | 35.6M | 29.0M |
| Other Non-Operating Income | -21.7M | -163.8M | -16.8M | -22.2M | -45.6M |
| Pre-tax Income | 16.9M | -63.1M | 61.7M | 13.3M | 56.4M |
| Income Tax | 9.8M | 36.5M | 19.7M | -2.6M | 14.4M |
| Effective Tax Rate % | 58.3% | 0.0% | 32.0% | -19.6% | 25.6% |
| Net Income | 7.0M | -99.6M | 42.0M | 15.9M | 42.0M |
| Net Margin % | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% |
| Key Metrics | |||||
| EBITDA | 137.6M | 192.5M | 171.2M | 151.3M | 156.9M |
| EPS (Basic) | $0.16 | $-2.15 | $0.91 | $0.35 | $0.95 |
| EPS (Diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 |
| Basic Shares Outstanding | 44566000 | 46245000 | 46222000 | 45521000 | 44262000 |
| Diluted Shares Outstanding | 44566000 | 46245000 | 46222000 | 45521000 | 44262000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Pacira BioSciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 158.5M | 276.8M | 153.3M | 104.1M | 585.6M |
| Short-term Investments | 79.9M | 207.8M | 125.3M | 184.5M | 70.8M |
| Accounts Receivable | 124.1M | 113.3M | 105.6M | 98.4M | 96.3M |
| Inventory | 152.9M | 125.3M | 104.4M | 96.1M | 98.6M |
| Other Current Assets | 32.6M | 21.9M | 21.5M | 15.2M | 14.8M |
| Total Current Assets | 548.0M | 745.1M | 510.0M | 498.3M | 866.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 41.8M | 49.2M | 61.0M | 70.9M | 76.4M |
| Goodwill | 408.5M | 426.0M | 809.7M | 867.0M | 914.3M |
| Intangible Assets | 368.1M | 426.0M | 483.3M | 540.5M | 624.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 146.2M | 166.0M | 180.5M | 187.5M | 175.4M |
| Total Non-Current Assets | 716.9M | 808.4M | 1.1B | 1.2B | 1.2B |
| Total Assets | 1.3B | 1.6B | 1.6B | 1.7B | 2.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.2M | 19.1M | 15.7M | 15.2M | 10.5M |
| Short-term Debt | 9.8M | 210.7M | 17.4M | 42.8M | 382.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 120.6M | 309.9M | 97.4M | 147.8M | 521.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 408.4M | 428.2M | 568.6M | 720.6M | 746.3M |
| Deferred Tax Liabilities | 4.2M | - | - | - | - |
| Other Non-Current Liabilities | 38.6M | 37.1M | 38.3M | 37.8M | 77.6M |
| Total Non-Current Liabilities | 451.2M | 465.2M | 606.9M | 758.4M | 823.8M |
| Total Liabilities | 571.8M | 775.2M | 704.3M | 906.2M | 1.3B |
| Equity | |||||
| Common Stock | 48.0K | 47.0K | 46.0K | 46.0K | 45.0K |
| Retained Earnings | -199.3M | -206.4M | -106.8M | -148.8M | -211.9M |
| Treasury Stock | 176.6M | 25.1M | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 693.1M | 778.3M | 870.1M | 775.0M | 730.4M |
| Key Metrics | |||||
| Total Debt | 418.2M | 638.9M | 586.0M | 763.4M | 1.1B |
| Working Capital | 427.4M | 435.2M | 412.6M | 350.6M | 344.9M |
Balance Sheet Composition
Pacira BioSciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 7.0M | -99.6M | 42.0M | 15.9M | 42.0M |
| Depreciation & Amortization | 91.0M | 78.8M | 75.6M | 91.5M | 28.5M |
| Stock-Based Compensation | 57.5M | 51.2M | 47.9M | 48.1M | 42.2M |
| Working Capital Changes | -43.9M | -22.9M | -14.1M | 6.1M | -25.1M |
| Operating Cash Flow | 108.5M | 29.3M | 169.4M | 131.7M | 119.2M |
| Investing Activities | |||||
| Capital Expenditures | -15.3M | -10.6M | -15.2M | -30.1M | -45.9M |
| Acquisitions | -16.7M | 0 | 0 | 0 | -420.0M |
| Investment Purchases | -142.3M | -252.2M | -144.4M | -400.7M | -628.7M |
| Investment Sales | 273.8M | 179.6M | 237.1M | 237.6M | 1.1B |
| Investing Cash Flow | 99.5M | -83.3M | 77.5M | -225.2M | -20.8M |
| Financing Activities | |||||
| Share Repurchases | -148.3M | -25.0M | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 101.0M | 287.5M | 149.6M | 0 | 363.8M |
| Debt Repayment | -317.8M | -210.9M | -330.3M | -427.7M | 0 |
| Financing Cash Flow | -372.9M | 15.1M | -187.8M | -428.9M | 717.8M |
| Free Cash Flow | 136.7M | 178.8M | 139.5M | 115.2M | 79.9M |
| Net Change in Cash | -164.9M | -38.9M | 59.2M | -522.4M | 816.2M |
Cash Flow Trend
Pacira BioSciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
154.00
Forward P/E
7.02
Price to Book
1.46
Price to Sales
1.46
PEG Ratio
-1.74
Profitability Ratios
Profit Margin
0.97%
Operating Margin
-1.17%
Return on Equity
0.96%
Return on Assets
1.48%
Financial Health
Current Ratio
4.54
Debt to Equity
60.34
Beta
0.20
Per Share Data
EPS (TTM)
$0.16
Book Value per Share
$16.86
Revenue per Share
$16.30
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PCRX | 1.1B | 154.00 | 1.46 | 0.96% | 0.97% | 60.34 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Dynavax Technologies | 1.8B | 54.60 | 3.41 | -7.14% | -13.13% | 54.15 |
| Ani Pharmaceuticals | 1.8B | 24.08 | 3.10 | 16.16% | 8.87% | 116.19 |
| Perrigo Company plc | 1.6B | 2,818.00 | 0.55 | -38.66% | -33.51% | 131.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.






